Chapter Update Summary

10/12/2018

5/2/2018

2/5/2018

1/18/2018

11/14/2016

2/18/2016

10/14/2015

7/31/2015

3/12/2015

5/21/2014

4/9/2014

  • New phase III results from the STRATEGY-PI and the STRATEGY-NNRTI trials of switching virologically suppressed patients to once-daily cobicistat/elvitegravir/emtricitabine/tenofovir DF

12/23/2013

6/7/2013

3/13/2013

10/4/2011

2/4/2011

10/18/2010

  • Updated data from the ARIES trial of switching from atazanavir/ritonavir to unboosted atazanavir
  • New data on switching from a boosted PI to raltegravir
  • New data on lipid improvements upon switching from abacavir/lamivudine to tenofovir/emtricitabine
  • New data on switching NNRTIs in virologically suppressed patients due to toxicity

3/19/2010

  • Updated with published data from the SWITCHMRK trial